Zentalis Pharmaceuticals, Inc.

The company is a clinical-stage biopharmaceutical enterprise focused on discovering and developing targeted cancer therapies. Its lead product candidate is azenosertib, an investigational, orally administered small-molecule WEE1 inhibitor designed to selectively halt DNA damage repair in tumor cells and induce cell death. The firm concentrates its clinical development efforts on oncology indications, particularly platinum-resistant ovarian cancer characterized by Cyclin E1 overexpression, while exploring applications in other solid tumors. Its target patient populations include individuals diagnosed with advanced ovarian malignancies and other solid tumors who have received prior therapies.

The enterprise conducts its clinical development and intellectual property activities internationally, holding patents and trademark registrations in jurisdictions including the United States, the United Kingdom, the European Union, Japan, and China. It operates without internal manufacturing facilities and relies entirely on independent contract manufacturing organizations to produce, package, and distribute its investigational drug candidates. The provided text does not state the location of the company's headquarters.

Summary of the business section of Zentalis Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, Zentalis had a total of 106 employees all of whom were full-time employees.”